Scedosporium prolificans

''Lomentospora prolificans'' is an emerging opportunistic fungal pathogen that causes a wide variety of infections in immunologically normal and immunosuppressed people and animals. It is resistant to most antifungal drugs and infections are often fatal. Drugs targeting the Class II dihydroorotate dehydrogenase (DHODH) proteins of ''L. prolificans'', ''Scedosporium'', ''Aspergillus'' and other rare moulds are the basis for at least one new therapy, Olorofim, which is currently in phase 2b clinical trials and has received breakthrough status by FDA. For information on all DHODH proteins, please see Dihydroorotate dehydrogenase.

History

The genus ''Lomentospora'' was erected by G. Hennebert and B.G. Desai in 1974 to accommodate a culture obtained from greenhouse soil originating from a forest in Belgium. The fungus, which they named ''Lomentospora prolificans'', was thought incorrectly to be related to the genus ''Beauveria'' - a group of insect-pathogenic soil fungi affiliated with the order Hypocreales. The genus name "Lomentospora" referred to the shape of the apex of the spore-bearing cell, which the authors interpreted to be a rachis resembling a bean pod of the sort constricted at each seed. The species epithet "prolificans" derived from the prolific nature of the mold's sporulation. The fungus was later independently described as ''Scedosporium inflatum'' by Malloch and Salkin in 1984 from a bone biopsy of the foot of a boy who had stepped on a nail. The species epithet "inflatum" referred to the characteristically swollen base of the spore-bearing cell which they recognized correctly to be an annelide. Malloch and Salkin did not observe a sexual state, however they recognized the fungus to be associated with the family Microascaceae, and suspected it to be allied with the genus ''Pseudallescheria''. In 1991, Guého and De Hoog re-examined a set of cultures of ''Scedosporium''-like fungi from clinical cases by careful morphological examination and the evaluation of DNA-DNA reassociation complementarity. Along with two strains from their own work, they found the cultures of Hennebert & Desai and Malloch & Salkin to constitute a single species which they confirmed to belong in the genus ''Scedosporium''. ''Lomentospora prolificans'' was then transferred to ''Scedosporium'' as ''S. prolificans'', and ''Scedosporium inflatum'' became a synonym. This synonymy has since been confirmed by phylogenetic analysis of the nuclear ribosomal internal transcribed spacer regions. Despite this change, and even as recently as 2012, the name ''Scedosporium inflatum'' has continued to appear in the medical literature.

In 2014 Lackner ''et al.'' proposed a move back to ''L. prolificans''.

Appearance

''Lomentospora prolificans'' produces small, delicate annellides with a distinct basal swelling peculiar to this species and absent in the closely related species, ''Scedosporium apiospermum''. Annellides necks become long and distinctly annellated with age. Annellides occur individually or in clusters irregularly along undifferentiated hyphae, frequently exhibiting a pronounced penicillate arrangement in older cultures. Conidia are smooth-walled, light to dark brown, 3–7 x 2–3 μm, accumulating in slime droplets at annelide apices. Colonies of ''Lomentospora prolificans'' are grey to brownish, spreading, with scant, cobweb-like aerial mycelium recalling a moth-eaten woolen garment. This species is sensitive to cycloheximide. As this species may be slow to emerge from clinical materials, specimens in which this agent is suspected often require an extended period of culture incubation (e.g., up to 4 weeks).

Ecology

''Lomentospora prolificans'' is a soil fungus, and has been found in the soils of ornamental plants and greenhouse plants. Along with other fungi, ''Lomentospora prolificans'' has been isolated from soils of ''Ficus benjamina'' and ''Schefflera actinophylla'' plantings in hospitals, suggesting that these materials have potential to serve as reservoirs of nosocomial fungal pathogens.

Human disease

''Lomentospora prolificans'' has been recognized as an agent of opportunistic human disease since the 1990s. This species is primarily associated with subcutaneous lesions arising from injury following traumatic implantation of the agent via contaminated splinters or plant thorns. The majority of ''Lomentospora prolificans'' infections in immunologically normal people remain localized, characteristically with bone or joint involvement. Disseminated infections from ''Lomentospora prolificans'' are largely limited to people with pre-existing immune impairment. Notably, ''Lomentospora prolificans'' exhibits varying tolerance to all currently available antifungal agents. This is particularly true of strains recovered from disseminated infections, and these infections carry a high mortality. ''Lomentospora prolificans'' has also been known to cause disseminated disease secondary to myeloblastic leukemia and following lung transplant. In otherwise healthy people, it was recorded as a cause of corneal infection following a lawn trimmer mishap, and bone infection following trauma.

Drug resistance

Infections caused by ''Lomentospora prolificans'' are recognized to be difficult to treat due to the tendency of this species to exhibit resistance to many commonly used antifungal agents. Successful control of disseminated ''Lomentospora prolificans'' infection can be obtained with a combination of voriconazole and terbinafine, but some strains are resistant to this treatment. Drugs that might also be of help are posaconazole, miltefosine and albaconazole. Albaconazole is in phase III clinical trials.

Notes

References

External links

Photos of ''Scedosporium prolificans'' on MycoBank

{{Use dmy dates, date=January 2021

Microascales
Fungi described in 1974